December 1, 2016 04:33 AM EST
Pharma

Star-crossed As­traZeneca strikes a drug dis­cov­ery deal with up­start Bi­cy­cle

Arsalan Arif

Founder

As­traZeneca has struck a dis­cov­ery deal with Bi­cy­cle Ther­a­peu­tics, a trans-At­lantic biotech which hopes to make a splash with a new breed of mol­e­cules …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­vo Nordisk’s Ca­griSe­ma shows 15.7% weight loss in sec­ond piv­otal tri­al

Beam shares promis­ing first clin­i­cal da­ta on gene edit­ing treat­ment for a lung and liv­er dis­ease 

How blue­bird's buy­out of­fer went from $100M up­front to $29M

Sun Phar­ma to ac­quire Check­point Ther­a­peu­tics and its an­ti-PD-L1 an­ti­body

Ex­clu­sive: Dai­ichi Sankyo, John­son & John­son part­ner with RNA de­liv­ery start­up No­sis Bio

sponsored

Obe­si­ty drug de­vel­op­ment—still room to grow

A service from the Financial Times